Related Experiment Video
Updated: Jan 6, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo
Amber L Fifield1, Paul D Hanavan2, Douglas O Faigel3
1School of Life Sciences, Arizona State University, Tempe, Arizona.
Abstract:
Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed by many different tumor types. QSOX1 catalyzes the formation of disulfide bonds in proteins. Because short hairpin knockdowns (KD) of QSOX1 have been shown to suppress tumor growth and invasion in vitro and in vivo, we hypothesized that chemical compounds inhibiting QSOX1 enzymatic activity would also suppress tumor growth, invasion, and metastasis. High throughput screening using a QSOX1-based enzymatic assay revealed multiple potential QSOX1 inhibitors. One of the inhibitors, known as "SBI-183," suppresses tumor cell growth in a Matrigel-based spheroid assay and inhibits invasion in a modified Boyden chamber, but does not affect viability of nonmalignant cells. Oral administration of SBI-183 inhibits tumor growth in 2 independent human xenograft mouse models of renal cell carcinoma. We conclude that SBI-183 warrants further exploration as a useful tool for understanding QSOX1 biology and as a potential novel anticancer agent in tumors that overexpress QSOX1.
Insights
A novel inhibitor, SBI-183, targeting Quiescin sulfhydryl oxidase 1 (QSOX1) effectively suppresses tumor growth and invasion. This discovery offers a potential new strategy for treating cancers overexpressing QSOX1.
Area of Science:
- Biochemistry
- Oncology
- Drug Discovery
Background:
- Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed in various tumor types.
- QSOX1's role in catalyzing disulfide bond formation is implicated in tumor growth and invasion.
Purpose of the Study:
- To investigate QSOX1 inhibitors as potential anticancer agents.
- To evaluate the efficacy of SBI-183 in preclinical cancer models.
Main Methods:
- High-throughput screening identified QSOX1 inhibitors.
- SBI-183 tested in spheroid and Boyden chamber assays for tumor cell growth and invasion.
- SBI-183 evaluated in xenograft mouse models of renal cell carcinoma.
Main Results:
- SBI-183 suppressed tumor cell growth and invasion without affecting nonmalignant cells.
- Oral administration of SBI-183 inhibited tumor growth in two distinct xenograft models.
- SBI-183 demonstrated specific inhibition of QSOX1 enzymatic activity.
Conclusions:
- SBI-183 is a potent inhibitor of QSOX1 with anticancer properties.
- SBI-183 shows promise as a novel therapeutic agent for QSOX1-overexpressing tumors.
- Further research into SBI-183 is warranted for its potential in cancer therapy and QSOX1 biology studies.
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
Pleiotropy
MicroRNAs
Inheritance of Chromatin Structures

